CELC

Celcuity's stock price has been significantly impacted over the past six months by several events. Despite FDA approval of REVTORPYK on July 14, 2026, the announced 'late third quarter 2026' commercial launch was perceived as an extended timeline, leading to a stock price decline of over 17% on July 15, 2026. The company reported a wider-than-expected fiscal Q2 2026 loss of $1.44 per share, missing analyst expectations, and saw a significant increase in Selling, General, and Administrative (SG&A) expenses to $35 million, raising concerns about profitability and burn rate. Analysts subsequently revised down fiscal year 2026 revenue estimates by 34% and increased forecast losses per share, pushing the projected breakeven date from 2027 to 2028, which further contributed to the stock's decline. Additionally, the stock was affected by a broader biotech market downturn. The company also conducted several stock offerings, including an underwritten offering of 3,871,000 shares at $15.50 in May 2024, raising $60 million; proposed public offerings for $150 million in convertible senior notes and $75 million in common stock in July 2025; and an upsized $500M convertible offering in June 2026.